Michael Shen

Cooley represented Beijing Tiannuo Jiancheng Pharmaceutical Technology, a joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in connection with a joint exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

Cooley advised Jiangsu Hengrui Pharmaceuticals, one of the largest pharmaceutical companies in China, on its licensing of global rights (excluding Greater China) for the development, production and commercialization of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco, a newly established Delaware company.

Cooley advised NKGen Biotech, a clinical-stage biotechnology company, on its business combination agreement with special purpose acquisition company Graf Acquisition Corp. IV – a combination that will result in NKGen becoming a publicly listed company.

Cooley advised Luqa Ventures, a dermatology specialty company, on its sale of all issued and outstanding shares to China Medical System (0867.HK). Following the transaction, Luqa became a wholly-owned subsidiary of CMS. Luqa has an extensive portfolio of prescription medicines, medical devices, medical aesthetic solutions and skin care products that meets the diversified needs of consumers in China and provides the market with safe and effective solutions for a broad range of skin conditions. This acquisition marked CMS’s first foray into the medical aesthetic market. Partner James Lu led the Cooley team advising Luqa Ventures on the transaction.